Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886046 | 0.94 | CHRM3 (0.62) | CHRM3CHRM2CHRM1KCNH2OPRM1 | |
| SCHEMBL4886779 | 0.85 | CHRM3 (0.52) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4888039 | 0.82 | CHRM3 (0.59) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL6312702 | 0.81 | CHRM4 (0.59) | CHRM3CHRM2CHRM4LTA4HKCNH2 | |
| SCHEMBL4887681 | 0.80 | CHRM3 (0.50) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4923231 | 0.78 | CHRM3 (0.56) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4464056 | 0.78 | OPRM1 (0.57) | CHRM3CHRM2CHRM4LTA4HKCNH2 | |
| SCHEMBL5718487 | 0.78 | OPRM1 (0.57) | CHRM3CHRM2CHRM4LTA4HKCNH2 | |
| SCHEMBL4879759 | 0.78 | CHRM3 (0.67) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4921992 | 0.78 | CHRM2 (0.55) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | claimed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | claimed |
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.